BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Telegram Restored on Apple App Store After Temporary Removal 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
(4) - EconoTimes)
BERKELEY, Calif., April 03, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 29, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of (i) inducement stock options to purchase an aggregate 114,000 shares of common stock and (ii) an inducement restricted stock unit award covering 1,800 shares of common stock, to nine new employees. These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $18.80 per share, the closing price of Dynavax’s common stock on April 2, 2018, the effective date of such grants. The stock options and restricted stock units vest as follows: (a) the stock options vest over a three-year period, with one-third of the shares subject to such awards vesting on the first anniversary of the award’s vesting commencement date, and 1/36th of the shares subject to such awards vesting monthly thereafter, subject to each such employee’s continued employment with Dynavax on such vesting dates; and (b) the restricted stock units vest on April 2, 2018, the effective date of such award.
Dynavax is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, Investor Relations & Corporate Communications
510.665.7269
[email protected]
